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Recent advances in molecular genetic studies have revealed many of the causative genes of retinitis pigmentosa (RP). These
achievements have provided clues to the mechanisms of photoreceptor degeneration in RP. Apoptosis is known to be a ﬁnal
common pathway in RP and, therefore, a possible therapeutic target for photoreceptor rescue. However, apoptosis is not a
single molecular cascade, but consists of many diﬀerent reactions such as caspase-dependent and caspase-independent pathways
commonly leading to DNA fractionation and cell death. The intracellular concentration of calcium ions is also known to increase
in apoptosis. These ﬁndings suggest that calpains, one of the calcium-dependent proteinases, play some roles in the process of
photoreceptor apoptosis and that calcium channel antagonists may potentially inhibit photoreceptor apoptosis. Herein, the eﬀects
of calpains and calcium channel antagonists on photoreceptor degeneration are reviewed.
1.Introduction
Retinitis pigmentosa (RP) represents a group of hereditary
retinal degenerations principally characterized by progres-
sive rod-dominant photoreceptor degeneration in the initial
stage and eventual cone photoreceptor degeneration in
later stages. Patients with RP mainly complain of night
blindness and photophobia in the early stage, followed by
gradual constriction of the visual ﬁeld, decreased visual
acuity, and color blindness in later stages. The preva-
lence of RP is roughly 1 in 4,000-5,000 people, and
the condition is common in both Asian and Western
countries. Signiﬁcant features of RP include heterogeneity
in both clinical and genetic characteristics. For instance,
the severity and progression of RP vary from patient to
patient even in the same family, despite aﬀected members
presumably sharing the same causative gene mutation.
Heredities are also heterogeneous, characterized by at least
3d i ﬀerent modes of inheritance, such as autosomal-
dominant, autosomal-recessive, and X-linked patterns. Since
a mutation in the rhodopsin gene was ﬁrst identiﬁed as
causing one type of autosomal-dominant RP [1], at least
48 diﬀerent causative genes have been identiﬁed (Ret-
Net: http://www.sph.uth.tmc.edu/retnet/disease.htm); how-
ever, many other putative causative genes and mutations
have yet to be identiﬁed. Molecular genetic studies have also
demonstrated that a primary lesion in RP involves photore-
ceptor and/or retinal pigment epithelial cells in which many
causative genes are speciﬁcally expressed under physiological
conditions. Photoreceptor or retinal pigment epithelial cells
are known to degenerate mostly through apoptosis [2],
which is now understood as a ﬁnal common pathway for
RP at the cellular level. As the mechanisms of photoreceptor
degeneration have been gradually elucidated, studies on
therapeutic approaches have dramatically increased, includ-
ing pharmacotherapy, cellular transplantation, gene therapy,
regenerative therapy, and retinal prosthesis. This paper
mainly focuses on studies examining the eﬀects of calcium
ions and calpains on photoreceptor apoptosis, as well as
pharmacological treatments for RP using calcium channel
antagonists.
2.Ge neticBac k gr o undo fRP
One of the most important breakthroughs in RP research
was the identiﬁcation of a point mutation (P23H) in the
r h o d o p s i ng e n ea sac a u s a t i v eg e n em u t a t i o nf o ro n ef o r mo f
autosomal-dominant RP [1, 3]. Since then, using a candidate
gene approach, various mutations in the rhodopsin gene and2 Journal of Ophthalmology
many other genes have been identiﬁed in several RP families.
These include mutations in the genes encoding β-a n dα-
subunits of rod cGMP-phosphodiesterase for autosomal-
recessive RP [4, 5] and peripherin/RDS (RDS: retinal
degenerationslow)forautosomal-dominantRP[6,7].These
ﬁndings in the early 1990s suggested to many researchers
that RP is caused by a single or one allelic pair of mutations
in one of the genes speciﬁcally or dominantly expressed in
photoreceptor cells. The candidate gene approach was also
relatively easy to perform once researchers suspected genes
already known to be retina speciﬁc as possible candidates
for RP. Many other genes and mutations in these genes were
then found to cause RP (Table 1). However, the candidate
gene approach is limited in that screening can only be
performed for known genes and involvement could not be
ascertained for previously unknown genes that might be
expressed not only in the retina, but also in other organs
or tissues in a ubiquitous fashion. For these reasons, genetic
linkage and/or association analyses have been performed
in combination with a candidate gene approach to identify
many other previously unpredictable genes as causative
genes for RP. This group includes PRPF31 [8], PRPF3
[9], PRPF8 [10], IMPDH1 [11], Mertk [12, 13], and CA4
[14] which are expressed in other tissues besides retina
(Table 1). These ﬁndings indicate that photoreceptors and
retinal pigment epithelium are much more active in protein
synthesis than any other tissues and show high levels of gene
expression and protein metabolism. In addition, molecular
genetic studies have disclosed that RP is genetically more
heterogeneous than it used to be considered and that the
genetic heterogeneity may be one explanation for the clinical
heterogeneity.
3.Photoreceptor Apoptosis as
aCommon Mechanism inRP
Despite the clinical and genetic heterogeneity, RP demon-
strates common features derived from rod-predominant
degeneration. This essential phenomenon allowed research-
ers to suspect some common mechanisms leading to
photoreceptor cell death once the patient carries a single
or one allelic pair of many causative gene mutations.
Apoptosisisageneticallyprogrammedmechanismthatleads
cells to death, and RP has been known to be initiated
by photoreceptor apoptosis as a ﬁnal common pathway
at the cellular level, irrespective of gene mutations. For
instance, apoptosis was detected in retinal degeneration 1
(rd1), rds, and rhodopsin mutant mice [2]. To date, many
pathways have been found for apoptosis itself, involving
caspases, cathepsins, calpains, apoptosis-inducing factor
(AIF), Fas, and more. Once abnormal and/or insuﬃcient
structural or metabolic stresses induced by a certain gene
mutation exceed predetermined thresholds that a cell can
tolerate, mechanisms of apoptosis are initiated that lead
to nuclear DNA fragmentation and subsequent cell death.
Many experimental studies have supported that caspase-
dependent or -independent apoptotic pathways are activated
during experimental retinal degeneration models [15, 16].
Table 1: List of causative genes of RP: retina speciﬁc and
nonspeciﬁc.
Category ADRP (20) ARRP (25) XLRP (2)
Retina speciﬁc CRX ABCA4 RP2
FSCN2 CERKL
GUCA1B CNGA1
NRL CNGB1
NR2E3 CRB1
PRPH2 EYES
RDH12 IDH3B
RHO LRAT
ROM1 NR2E3
RP1 NRL
RP9 PDE6A
SEMA4A PDE6B
PRCD
PROM1
RBP3
RGR
RHO
RLBP1
RP1
RPE65
SAG
SPATA7
TUP1
USH2
Retina nonspeciﬁc CA4 MERTK RPGR
IMPDH1
KHLH7
PRPF3
PRPF8
PRPF31
SNRNP200
TOPORS
Abbreviations are listed in Ret:Net: http://www.sph.uth.tmc.edu/retnet/
disease.htm.
Apoptosis can thus be considered as a therapeutic target as
it plays many roles in retinitis pigmentosa [17, 18].
Calpains [EC 3.4.22.17], a group of calcium-dependent
cysteine proteases, play some important roles in caspase-
independent photoreceptor apoptotic pathways with light-
induced retinal damage [19] and in rd1 mice [20, 21]a n d
Royal College of Surgeons (RCS) rats [22]a sm o d e l so f
retinal degeneration. Calpains are also involved in calcium-
induced cell death in a murine photoreceptor-derived cell
line [23, 24]. There is little doubt that intracellular con-
centrations of calcium ion were elevated in apoptosis [25–
28]. As calcium inﬂux is actually elevated in degenerating
rd1 rod photoreceptors [20, 29], calpains are suspected to
play important roles in photoreceptor apoptosis in RP. In
addition, calpain inhibitors and calcium channel blockers
appear to oﬀer reasonable candidates at least in part asJournal of Ophthalmology 3
pharmacotherapeutic agents for RP. Transient inhibitory
eﬀects of calpain inhibitors on photoreceptor apoptosis in
RCS rats have recently been described by Mizukoshi et al.
[22].
4. Effects of CalciumIon on
Photoreceptor Apoptosis
As mentioned above, intracellular concentrations of calcium
ion are increased in apoptosis [20, 25–29]. Intracellular
calcium ions are provided through several types of calcium
channels and transporters located on cell membranes, endo-
plasmic reticulum, and mitochondria. Cyclic-nucleotide-
gated cation channels (CNGCs) are located in the outer
segment and closed by depletion of cGMP as a result of the
phototransduction reaction triggering hyperpolarization. L-
type voltage-gated calcium channels (VGCCs) are located
in the cell body and synaptic terminal and are closed
by hyperpolarization of the cell membrane induced by
phototransduction. Steele Jr. et al. [30] suggested that the
average concentration of calcium in the terminal ranges
from ∼350nM in hyperpolarized light-adapted cells to more
than 39μM in cells depolarized to dark potentials in sala-
mander rods and cones. In addition to CNGC and VGCC,
intracellular concentrations of calcium ions are regulated
by many other factors, such as plasma membrane calcium
ATPase, store-operated calcium entry, calcium stores in the
endoplasmic reticulum, and mitochondria (Figure 1). Under
pathological conditions, like those in rd1 mice, intracellular
calcium levels signiﬁcantly increase in rods, even before
the detection of apoptotic cells [29]. The marked elevation
of intracellular concentrations of calcium ions activates
downstream reactions, including hydrolytic enzymes like
calpains, and eventually leads to cell death [25]. Excessive
calcium inﬂux is initiated in the cytosol and subsequently in
mitochondria in rd1 mouse [29], suggesting that increased
calcium ions may aﬀect many biochemical cascades and
reactionsnotonlyinthecytosolbutalsointhemitochondria
[31,32].Asmentionedabove,increasedintracellularcalcium
concentrations activate calpains, leading to the activation
of both caspase-dependent and -independent apoptotic
pathways. First, as a caspase-dependent pathway, calpains
activate caspase 12, which sequentially activates caspases 9,
3, 4, and 7 and ﬁnally apoptosis is upregulated. Second,
cytosolic calpains further activate cathepsins and mitochon-
drial calpains activate AIF, which subsequently translocates
from mitochondria to the nucleus [22]. This reaction has
been speculated to represent one of the caspase-independent
pathways of apoptosis [33, 34].
5.Ca2+ Channel Antagonists for Photoreceptor
Apoptosis in Animal Experiments
Since Frasson et al. [35] ﬁrst reported the eﬀects of D-
cis-diltiazem, a benzothiazepin calcium channel antagonist
which blocks both CNGC and VGCC, on photoreceptor
protection in rd1 mice, several investigators have reported
positive and negative eﬀects of calcium channel blockers
on animal models of RP [19–21, 36–43]. Since rd1 is
caused by a mutation in the gene encoding the β-subunit
of rod cGMP-phosphodiesterase, one of the key enzymes
in the phototransduction pathway, CNGCs located in the
outer segment cannot be closed despite light stimulation
in the rod photoreceptor cells. Inhibition of light-induced
hyperpolarization, caused by a mutation in the rod cGMP-
phosphodiesterase gene, also does not close VGCC. These
phenomena increase calcium inﬂux in both outer and inner
segments in rd1 mice. The intracellular concentration of
calcium ions is subsequently elevated, leading to photore-
ceptor apoptosis [35], possibly by upregulation of calpains
and other proteins [28]. Sanges et al. [20] demonstrated that
systemic administration of D-cis-diltiazem reduced intra-
cellular concentrations of calcium, downregulating calpains
and photoreceptor apoptosis in rd1 mice. Direct inhibitory
eﬀects of D-cis-diltiazem on CNGC [44] or L-type VGCC
[39] have been reported, and D-cis-diltiazem eﬀectively
blocks photoreceptor light damage in mouse models by
inhibiting photoreceptor apoptosis [19]. In contrast, L-cis
isomer inhibits L-type VGCC similarly to D-cis isomer
[45]. The diﬀerence in action between D-cis- and L-cis-
diltiazems on photoreceptor neuroprotection [35] suggests
that CNGC might also be important for photoreceptor
neuroprotection [44]. Read et al. [46] also reported that the
β-subunit of VGCC knock-out rd1 mice showed retardation
of photoreceptor degeneration, suggesting that blockage of
calcium inﬂux may partially contribute to photoreceptor
rescue in these animal models although it did not prevent
photoreceptor degeneration. Despite these studies, however,
Pawlyk et al. [36] and Takano et al. [41] found no rescue
eﬀects of D-cis-diltiazem on retinal degeneration in rd1
m i c e ,a n dB u s he ta l .[ 42] also reported that D-cis-diltiazem
was ineﬀective for photoreceptor rescue in rhodopsin P23H
transgenic rats.
While the eﬀects of diltiazem on animal models of
retinal degeneration remain controversial, another type of
calcium channel blocker, nilvadipine, a member of the
dihydropyridinederivatives,isanothercandidatetherapeutic
agent for RP. Nilvadipine has low-voltage-activated calcium
blocking actions in addition to L-type high-voltage calcium
blocking actions. The hydrophobic nature induced by the
chemical structure of nilvadipine allows high permeability
to the central nervous system, including the retina [47].
Systemic administration of nilvadipine has been shown to be
eﬀective for protecting photoreceptors in RCS rats [37, 40],
rd1 mice [41], and heterozygous rd2 (rds) mice [43]. In
addition to direct eﬀects of calcium channel blockers on
intracellular concentrations of calcium ion in photoreceptor
cells, other indirect eﬀects are expected such as increased
expression of ﬁbroblast growth factor (FGF) 2 [40, 41]
and ciliary neurotrophic factor (CNTF) [43] in the retina,
and increased choroidal blood ﬂow [48]. Since FGF2 and
CNTF are known to exert photoreceptor-protective eﬀects
[49–56], upregulating such intrinsic neurotrophic factors
by nilvadipine may demonstrate beneﬁcial eﬀects against
RP. CNTF has also been applied as a clinical trial for
RP [57]. In addition, oxidative stress may be involved in
photoreceptor death in RP [58–63], and nilvadipine has4 Journal of Ophthalmology
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Figure 1: Schematic view of calcium channels and transporters in the rod-photoreceptor. Abbreviations: CNGC, cyclic-nucleotide-gated
cation channel; VGCC: voltage-gated calcium channel; PMCA: plasma membrane calcium ATPase; SOCE: store-operated calcium entry;
ER: endoplasmic reticulum; SERCA: sarcoplasmic-endoplasmic reticulum Ca2+-ATPase; IP3R: inositol 1, 4, 5-triphoaphate receptor; RyR:
ryanodine receptor. Ca2+ stock and release from the mitochondria are mediated by Ca2+ uniporter channels and Na+/Ca2+ transporters.
the highest antioxidant potency among calcium channel
blockers [64]. The direct eﬀects of calcium channel blockers
on photoreceptor calpains have not yet been studied. Studies
involving calcium channel antagonists are listed in Table 2.
As the eﬀects of calcium channel blockers on photoreceptor
rescue remain controversial, further biochemical studies
are required in order to facilitate our understanding of
the mechanisms of photoreceptor degeneration induced by
various types of gene mutations, the eﬀects of intracellular
calcium ions on downstream reactions, and the eﬀects of
calcium channel blockers on both concentrations of calcium
ions and downstream reactions in various types of hetero-
geneous conditions of RP. Although human RP is caused
by various kinds of heterogeneous causative gene mutations,
our understanding regarding photoreceptor degeneration in
RP is still limited to relatively small numbers of experimental
models of RP.
6.HumanTrials
Although human RP is genetically heterogeneous, possible
rescue eﬀects of calcium channel blockers on photoreceptor
degeneration in certain animal models of RP, such as rd1
and rds mice and RCS rats, have encouraged researchers to
expect therapeutic eﬀects of calcium channel blockers for
RP. Pasantes-Morales et al. [65] reported that a combination
of D-cis-diltiazem, taurin, and vitamin E has beneﬁcial
eﬀects on the visual ﬁeld progression, although the study did
not clarify whether diltiazem alone demonstrated beneﬁcial
eﬀects. Ohguro [66] reported the photoreceptor rescue
eﬀects of nilvadipine in a small patient group. We expanded
his nilvadipine study for RP patients to conﬁrm the results.
Although both treated and control groups are still small,
our results have shown signiﬁcant retardation of the mean
deviation (MD) slope as calculated by the central visual ﬁeld
(HumphryVisualFieldAnalyzer,10-2Program)afteramean
of 48 months of observation [67]. As these pilot studies are
small-sized and cannot completely exclude possible biases, a
large-scale, randomized, multicenter human trial of calcium
channelblockersisrequiredinordertoevaluatetheireﬃcacy
as therapeutic agents for RP.
7.FutureInsights
As pharmacotherapeutic agents for RP, vitamin A [68,
69] and lutein [70] are reportedly eﬀective in slowing
RP, and carbonic anhydrase inhibitors appear eﬀective for
reducing chronic cystoid macular edema [71, 72], although
the basic molecular mechanisms underlying these actions
remain unclear. Eﬀects of calcium channel blockers have
been speculated based on the molecular mechanisms in
RP identiﬁed in recent molecular genetic [4] and animal
studies [20, 35] of RP and also research on neuroprotection
for glaucoma [73]. In addition to previous pilot studies,
large-scale human trials to examine the eﬀects of calcium
channel blockers in the progression of RP are needed toJournal of Ophthalmology 5
Table 2: Photoreceptor rescue by calcium channel antagonists.
Authors Year Ref.
Supportive
Diltiazem on rd1 mouse Frasson et al. 1999 [35]
Diltiazem on rd1 mouse Sanges et al. 2006 [20]
Diltiazem on light damage Vallaza-Deschamps et al. 2005 [19]
Calcium channel knockout on rd1 Read et al. 2002 [46]
Nilvadipine on rd1 mouse Takano et al. 2004 [41]
Nilvadipine on RCS rat Yamazaki et al. 2002 [37]
Nilvadipine on RCS rat Sato et al. 2003 [40]
Nilvadipine on rd2 (rds) mouse Takeuchi et al. 2008 [43]
Negative
Diltiazem on rd1 mouse Pawlyk et al. 2002 [36]
Diltiazem on rd1 mouse Takano et al. 2004 [41]
Diltiazem on pde β knock-out dog Pearce-Kelling et al. 2001 [21]
Diltiazem on rhodopsin P23H rat Bush et al. 2000 [42]
obtain solid evidence-based results. Since calcium channel
blockers may not eﬀectively block enough calcium inﬂux
to rescue degenerating photoreceptors depending on the
kinds of gene mutations, downstream reactions like calpains
should be considered when planning therapy. Eﬀects of
calpain inhibitors on human RP patients should also be
examined in the future. As other modern technologies
have advanced, new therapeutic modalities including gene
therapy, retinal prostheses, and regenerative medicine have
become increasingly developed, and some applications of
thesetechnologiesarenowcommerciallyavailable.Ofnoteis
the fact that pharmacotherapeutic agents aimed at photore-
ceptor rescue can be used in combination with gene therapy
and regenerative medicine.
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